Lifestyle · Exercise

Tirzepatide may trigger exercise-induced anaphylaxis, which resolves upon discontinuation of the drug.

A patient developed exercise-induced anaphylaxis after initiating tirzepatide, a dual GIP/GLP-1 receptor agonist. After discontinuing tirzepatide, the exercise-induced anaphylaxis resolved. This suggests a causal relationship between tirzepatide and exercise-induced anaphylaxis.

1 min readUpdated Jul 8, 20260 RCTsView structured evidence →
Evidence Score32/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Tirzepatide may trigger exercise-induced anaphylaxis, which resolves upon discontinuation of the drug. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).

The Claim

Tirzepatide may trigger exercise-induced anaphylaxis, which resolves upon discontinuation of the drug.

This conclusion is most relevant to: A single patient with exercise-induced anaphylaxis after starting tirzepatide.

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • Exercise-induced anaphylaxis with a cofactor of GIP/GLP-1 receptor agonist: A case report. (The journal of allergy and clinical immunology. Global, 2026) —

How It Works

The proposed biological pathway:

  • Tirzepatide activates GIP/GLP-1 receptors
  • May alter mast cell or immune response during exercise
  • Cofactor of exercise triggers anaphylaxis
  • Discontinuation removes trigger, leading to resolution

Who Might Benefit

Evidence fit by population:

  • A single patient with exercise-induced anaphylaxis after starting tirzepatide

Limitations & Caveats

Important context when interpreting this evidence:

  • Single case report, not generalizable
  • No control group or blinding
  • Potential confounding factors not controlled

Frequently Asked Questions

What is tirzepatide?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist used for type 2 diabetes and weight management.

Can exercise-induced anaphylaxis be caused by medications?

Yes, certain medications can act as cofactors, increasing the risk of exercise-induced anaphylaxis, as seen in this case with tirzepatide.

Does stopping tirzepatide always resolve exercise-induced anaphylaxis?

In this single case report, discontinuation led to resolution, but more evidence is needed to confirm this effect in other patients.

Is exercise-induced anaphylaxis common with GLP-1 receptor agonists?

This is a rare reported case; no widespread evidence suggests a common association, but clinicians should be aware of the potential risk.

References

  1. 1.Chong AC, Elshaer A, Diaz-Menindez M, Squire JD, Wonnaparhown AM, Freeman CM. “Exercise-induced anaphylaxis with a cofactor of GIP/GLP-1 receptor agonist: A case report..” The journal of allergy and clinical immunology. Global, 2026. PMID: 42405354 DOI: 10.1016/j.jacig.2026.100751
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.